Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Red Tree Venture Capital is an early-stage life science venture firm founded in 2020 and based in Redwood City, California. The firm was established to leverage relationships with leading West Coast academic and research institutions, aiming to source innovative life science companies. In 2022, Red Tree closed its inaugural fund, Red Tree Venture Capital Fund I, raising a total of $272 million to invest in transformative science.
Since its inception, Red Tree has focused on addressing significant unmet medical needs, particularly in the fields of oncology, neurology, and immunology. The firm has built a reputation for its West Coast-centric investment strategy, which emphasizes early-stage funding for companies developing first-in-class and best-in-class therapeutics. Red Tree's connections with premier institutions such as Stanford University and the University of California system enhance its ability to identify and support breakthrough innovations in life sciences.
Red Tree Venture Capital employs a West Coast-centric investment strategy, primarily targeting early-stage companies developing first-in-class and/or best-in-class therapeutics. The firm concentrates on significant unmet needs in oncology, neurology, and immunology. Red Tree aims to provide initial institutional capital to approximately half of the companies it funds, supporting breakthrough science from seed, preclinical, or early clinical stages.
The firm invests across various stages, including pre-seed, seed, seed-plus (extension), and Series A. Red Tree's check sizes typically align with the early funding needs of life science startups, allowing them to advance their innovative solutions effectively. The firm seeks to partner with founders who demonstrate a strong commitment to addressing critical healthcare challenges through scientific advancements.
Red Tree Venture Capital has invested in several companies connected to premier West Coast institutions, including Stanford University, the University of California, San Francisco, and the University of California, Los Angeles. Notable portfolio companies include:
These companies exemplify Red Tree's commitment to supporting transformative science and addressing critical healthcare challenges.
Heath Lukatch, Ph.D.: Co-Founder and Managing Partner. Heath has extensive experience in the life sciences sector, having previously worked at leading venture firms and focusing on early-stage investments.
Jennifer Cochran, Ph.D.: Co-Founder and Chief Scientific Advisor. Jennifer brings a wealth of scientific expertise and has a strong background in biotechnology and therapeutics development.
Jeremy Caldwell, Ph.D.: Managing Director. Jeremy has a proven track record in venture capital and has led numerous successful investments in the life sciences space.
In 2022, Red Tree Venture Capital successfully closed its inaugural fund, raising $272 million to invest in transformative life science innovations. The firm has been actively sourcing innovative life science companies through its relationships with leading West Coast academic and research institutions.
As of 2023, Red Tree continues to expand its portfolio, focusing on early-stage investments in biotech and healthcare sectors. The firm remains committed to addressing significant unmet medical needs through its strategic investments.
What are Red Tree Venture Capital's investment criteria?
Red Tree focuses on early-stage life science companies, particularly those developing first-in-class and best-in-class therapeutics. The firm emphasizes significant unmet needs in oncology, neurology, and immunology.
How can I pitch to Red Tree Venture Capital?
Founders can reach out through the firm's website or contact them directly. A well-prepared pitch deck should include details about the technology, market opportunity, team, and financial projections.
What makes Red Tree different from other venture firms?
Red Tree's unique focus on life sciences and its strong connections with leading West Coast academic institutions provide a competitive advantage in sourcing innovative companies.
What is the typical check size for investments?
Red Tree invests across various stages, including pre-seed, seed, seed-plus, and Series A, with check sizes tailored to the early funding needs of life science startups.
What is Red Tree's geographic focus?
The firm primarily invests in North America, specifically targeting companies based in the United States.
What kind of support does Red Tree provide to portfolio companies?
Red Tree offers not only capital but also strategic insights and access to its network of academic and research institutions, which can be invaluable for early-stage companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.